1. Home
  2. SANG vs IPHA Comparison

SANG vs IPHA Comparison

Compare SANG & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sangoma Technologies Corporation

SANG

Sangoma Technologies Corporation

HOLD

Current Price

$3.73

Market Cap

123.6M

Sector

Technology

ML Signal

HOLD

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

HOLD

Current Price

$1.83

Market Cap

189.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SANG
IPHA
Founded
1984
1999
Country
Canada
France
Employees
N/A
163
Industry
Computer Software: Programming Data Processing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
123.6M
189.5M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
SANG
IPHA
Price
$3.73
$1.83
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$5.75
AVG Volume (30 Days)
6.9K
139.5K
Earning Date
05-06-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$180.36
Revenue Next Year
$4.98
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.48
$1.18
52 Week High
$6.46
$2.63

Technical Indicators

Market Signals
Indicator
SANG
IPHA
Relative Strength Index (RSI) 41.28 53.44
Support Level $3.71 $1.72
Resistance Level $5.36 $1.82
Average True Range (ATR) 0.18 0.21
MACD 0.00 -0.01
Stochastic Oscillator 37.34 38.46

Price Performance

Historical Comparison
SANG
IPHA

About SANG Sangoma Technologies Corporation

Sangoma Technologies Corp is a provider of hardware and software components that enable or enhance Internet Protocol Communications Systems for both telecom and datacom applications. It is engaged in the development, manufacturing, distribution, and support of voice and data connectivity components for software-based communication applications. Its product includes data and telecom boards for media and signal processing, as well as gateway appliances and software. The Company sells into two geographic centers: USA and Other countries. Key revenue is generated from USA.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

Share on Social Networks: